The role of circulating tumor DNA (ctDNA) in urothelial cancers
Jeanny B. Aragon-Ching
Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) : 1002317
The role of circulating tumor DNA (ctDNA) in urothelial cancers is a rapidly evolving area of research. Urothelial cancer is the most common subtype of bladder cancer, and biomarkers that predict response or prognosticate outcomes have been long sought after. Tumor-informed ctDNA assays have been utilized in several other cancers and increasingly used in both muscle invasive bladder cancer (MIBC) and metastatic urothelial cancer (mUC) to inform treatment decision-making. While a universal consensus on ctDNA testing has not been fully defined and discussed herein, understanding its benefits and limitations is important to help guide the practical application in the clinic.
Circulating tumor DNA (ctDNA) / bladder cancer / urothelial cancer / muscle invasive bladder cancer (MIBC) / metastatic urothelial cancer (mUC)
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
Christensen E, Birkenkamp-Demtröder K, Sethi H, Shchegrova S, Salari R, Nordentoft I, |
| [13] |
|
| [14] |
|
| [15] |
Powles T, Assaf ZJ, Degaonkar V, Grivas P, Hussain M, Oudard S, |
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
Vandekerkhove G, Todenhöfer T, Annala M, |
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
/
| 〈 |
|
〉 |